Business, energy, technology, markets and global industry news from Business News Today

diffuse large B-cell lymphoma

PharmaDeviceNews diffuse large B-cell lymphoma
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Representative image showing blood cancer clinical research and treatment review, reflecting Incyte’s tafasitamab frontMIND trial update in high-risk diffuse large B-cell lymphoma.
Pharma & Biotech

Is Incyte’s tafasitamab regimen strong enough to challenge first-line DLBCL standards?

Find out how Incyte’s tafasitamab data could reshape first-line high-risk DLBCL treatment after frontMIND’s EHA 2026 readout.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More
Pharma & Biotech

Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?

Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.

Read More
Pharma & Biotech

How HUTCHMED (China) Limited is positioning HMPL-760 against established BTK therapies in lymphoma care

Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.

Read More
Pharma & Biotech

How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma

AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.

Read More
Pharma & Biotech

Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum

Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.

Read More
Representative image illustrating lymphoma research and combination chemotherapy, relevant to emerging first-line DLBCL treatments like tafasitamab plus R-CHOP.
Pharma & Biotech

Incyte’s tafasitamab clears pivotal trial in high-risk DLBCL—will it shift front-line treatment?

Incyte Corporation has announced positive topline results from its Phase 3 frontMIND trial evaluating tafasitamab (marketed as Monjuvi/Minjuvi) and lenalidomide in combination with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of progression-free survival (PFS) and a key secondary endpoint of event-free survival (EFS), setting the stage for

Read More